|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2005-9-12
|
|
pubmed:abstractText |
When cyclophosphamide (120 mg/kg) is used for hematopoietic cell transplant, the increased area under the curve of carboxyethylphosphoramide mustard (AUC(CEPM)) is related to liver toxicity and death. We determined the feasibility of dose-adjusting cyclophosphamide to a preset metabolic endpoint (AUC(CEPM), 325 +/- 25 micromol/L.h). In 20 patients blood sampling was done over a 16-hour period after administration of 45 mg/kg cyclophosphamide; AUC(CEPM) from 0 to 16 hours was calculated by noncompartmental analysis. The expected AUC(CEPM) for 0 to 48 hours was estimated, and the second cyclophosphamide dose was determined. The mean second cyclophosphamide dose was 42 mg/kg, and the mean total cyclophosphamide dose was 86 mg/kg (range, 54-120 mg/kg). The mean AUC(CEPM) for the time from 0 to 48 hours was 296 micromol/L.h (95% confidence interval, 275-317 micromol/L.h). A retrospective analysis indicated that AUC(CEPM) could be more accurately predicted by use of a population pharmacokinetic model. We conclude that metabolism-based dosing of cyclophosphamide is feasible and that a lower cyclophosphamide dose does not affect engraftment.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0009-9236
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
78
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
298-308
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:16153400-Adolescent,
pubmed-meshheading:16153400-Adult,
pubmed-meshheading:16153400-Aged,
pubmed-meshheading:16153400-Antineoplastic Agents, Alkylating,
pubmed-meshheading:16153400-Area Under Curve,
pubmed-meshheading:16153400-Bayes Theorem,
pubmed-meshheading:16153400-Blood Platelets,
pubmed-meshheading:16153400-Cohort Studies,
pubmed-meshheading:16153400-Cyclophosphamide,
pubmed-meshheading:16153400-Drug Delivery Systems,
pubmed-meshheading:16153400-Drug-Induced Liver Injury,
pubmed-meshheading:16153400-Female,
pubmed-meshheading:16153400-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:16153400-Humans,
pubmed-meshheading:16153400-Male,
pubmed-meshheading:16153400-Middle Aged,
pubmed-meshheading:16153400-Models, Biological,
pubmed-meshheading:16153400-Neutrophils,
pubmed-meshheading:16153400-Phosphoramide Mustards
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Metabolism-based cyclophosphamide dosing for hematopoietic cell transplant.
|
|
pubmed:affiliation |
Gastroenterology/Hepatology Section, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
